Drug Profile

Rucaparib - pharmaand GmbH

Alternative Names: AG-014699; AG-14699; CO-338; PF-01367338; PF-1367338; Rubraca; Rucaparib phosphate - pharmaand GmbH

Latest Information Update: 06 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cancer Research UK
Developer Alliance for Clinical Trials in Oncology; Bristol-Myers Squibb; Cancer Research UK; Clovis Oncology; Clovis Oncology [CEASED]; National Cancer Institute (USA); NHS Greater Glasgow and Clyde; Roche; Tolmar; UNICANCER; University of Colorado at Denver; University of Oklahoma; University of Utah
Class 3-ring heterocyclic compounds; Amines; Antineoplastics; Azepines; Fluorine compounds; Indoles; Small molecules
Mechanism of Action Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase 3 inhibitors; Poly(ADP-ribose) polymerase-1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Ovarian cancer
New Molecular Entity Yes

Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer
Phase II Breast cancer; Cervical cancer; Endometrial cancer; Gastric cancer; Malignant-mesothelioma; Pancreatic cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
Suspended Malignant melanoma

27 Feb 2026 Clovis Oncology and University of Colorado completes a phase II clinical trials in Endometrial cancer (Second-line therapy or greater, Recurrent, Metastatic disease) in USA (PO) (NCT03617679)
19 Dec 2025 Launched for Prostate cancer (First-line therapy, Hormone refractory, Metastatic disease) in USA (PO)
19 Dec 2025 Registered for Prostate cancer (First-line therapy, Hormone refractory, Metastatic disease) in USA (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com